EMA director still 'open-minded' on data disclosure policy
This article was originally published in SRA
Executive Summary
As the European Medicines Agency's management board prepares to examine the agency's controversial draft policy on clinical trial data disclosure at its meeting tomorrow, the EMA's executive director Guido Rasi has said he is willing to explore more "user-friendly" approaches to allay researchers' concerns over limitations on access to trial data1.